Healthcare Industry News: Glaucoma
News Release - October 16, 2007
CeNeRx BioPharma Adds Dr. Daniel Burch as Chief Medical OfficerFormer GlaxoSmithKline Neurosciences Head Brings Broad Research & Development Expertise to Help Advance the Company's CNS Portfolio
RESEARCH TRIANGLE PARK, N.C., Oct. 16 (HSMN NewsFeed) -- CeNeRx BioPharma, Inc., a biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system, today announced the addition of Daniel Burch, M.D., M.B.A. as Executive Vice President of R&D and Chief Medical Officer. Dr. Burch will play a critical role in building and advancing the CeNeRx product portfolio and leading its research and development programs.
"We are delighted to have Dan join the CeNeRx team," said Barry Brand, CEO of CeNeRx BioPharma. "We expect his expertise and proven track record of leadership in bringing significant drugs to the market will contribute greatly to our mission of developing important new CNS medicines for underserved conditions. His deep knowledge of the global regulatory process and successful partnering experience should be very valuable to CeNeRx as we advance our current product candidates and potentially expand our pipeline programs."
Dr. Burch's broad industry experience includes 15 years of developing new medicines at Abbott Laboratories, SmithKline Beecham and GlaxoSmithKline (GSK). His most recent post at GSK was Senior Vice President and Head of the Neurosciences Medicine Development Centre, where he was responsible for building and managing the global neuroscience drug development portfolio and was accountable for delivering important CNS products addressing depression, movement disorders, pain and Alzheimer's disease. In his pharmaceutical industry career, Dr. Burch has worked to establish new business ventures and has held leadership positions in a variety of therapeutic areas and functions.
"CeNeRx is an exciting opportunity with a pipeline of novel potential medicines addressing areas of high unmet need," said Dr. Burch. "I look forward to working with the CeNeRx team to advance the company's lead RIMA series, which appears to hold great promise as an important addition to the management of major depressive disorder, as well as its selective cannabinoid program with significant potential in pain, obesity and other CNS-related conditions."
Dr. Burch received a B.S. degree from the University of South Carolina, an M.D. degree from the Vanderbilt University School of Medicine and an M.B.A. degree from the Wharton School at the University of Pennsylvania. He is a co- author of numerous scientific papers and is the inventor on several patents. Among other professional activities, Dr. Burch has served on the National Institute of Medicine's Forum on Neurosciences and Nervous System Disorders.
About CeNeRx BioPharma
CeNeRx (SEN-er-ex) is a privately held clinical stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compounds, reversible inhibitors of monoamine oxidase, or RIMAs, are in late preclinical and Phase I development for the treatment of major depressive disorder. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile. The company is also developing its preclinical pipeline of selective cannabinoid compounds for the treatment of pain, Glaucoma and obesity. More information about CeNeRx BioPharma can be found at www.cenerx.com.
Source: CeNeRx BioPharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.